Linganisha mbinu
Pitia mbinu ulizochagua bega kwa bega; safu zinazotofautiana zinaangaziwa.
| Uhusiano wa In Vitro-In Vivo× | Fisiolojia ya Msingi ya Farmakokinetiki× | |
|---|---|---|
| Nyanja | Famakolojia | Famakolojia |
| Familia | Process / pipeline | Process / pipeline |
| Mwaka wa asili≠ | 1995 | 1997 |
| Mwanzilishi≠ | Gordon Amidon | Ivan Nestorov |
| Aina≠ | bioavailability prediction | predictive modeling |
| Chanzo asilia≠ | Amidon, G. L., Lennernäs, H., Shah, V. P., & Crison, J. R. (1995). A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharmaceutical Research, 12(3), 413-420. DOI ↗ | Nestorov, I. (1997). Sensitivity analysis of pharmacokinetic and pharmacodynamic systems. Journal of Pharmacokinetics and Biopharmaceutics, 25(4), 529-543. link ↗ |
| Majina mbadala≠ | IVIVC | PBPK, PBPK modeling |
| Zinazohusiana | 3 | 3 |
| Muhtasari≠ | IVIVC is a mathematical relationship between in vitro and in vivo properties of a drug, developed to predict oral bioavailability from dissolution data. Introduced by Amidon and colleagues in the 1995 Biopharmaceutics Classification System, it bridges laboratory measurements and clinical outcomes to streamline drug development. | PBPK is a mechanistic modeling framework that uses physiological parameters, tissue properties, and drug-specific attributes to predict drug concentration time profiles in the body. Developed rigorously in the 1990s by researchers including Nestorov, PBPK integrates anatomy, biochemistry, and kinetics to enable rational drug development, bridging in vitro data to clinical outcomes. |
| ScholarGateSeti ya data ↗ |
|
|